Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24854593 | 0.85 | GRM7 (0.43) | GRM7KRAS | |
| SCHEMBL21733780 | 0.80 | CYP4F2 (0.35) | GRM7 | |
| SCHEMBL30834498 | 0.80 | CYP4F2 (0.35) | GRM7 | |
| SCHEMBL21734021 | 0.78 | KRAS (0.38) | GRM7KRAS | |
| SCHEMBL21734019 | 0.77 | MAPT (0.33) | — | |
| SCHEMBL21733818 | 0.73 | KRAS (0.51) | KRAS | |
| SCHEMBL30834503 | 0.72 | GRM7 (0.32) | GRM7KRAS | |
| SCHEMBL21722189 | 0.72 | GRM7 (0.32) | GRM7KRAS | |
| SCHEMBL21733500 | 0.70 | KRAS (0.36) | GRM7KRAS | |
| SCHEMBL21733527 | 0.70 | MEN1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230002345-A1 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-05 | — | — | US | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | GRM7 2937/4885KRAS 1/4885 |
| US-20230002345-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | GRM7 2937/4885KRAS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.